in vivo News and Research

RSS

Enhancing vaccine efficiency through encapsulation

A work published in Vaccine, and led by the Institut de Biotecnologia i de Biomedicina (IBB – UAB) and ICN2, studies the biodistribution and immunological efficacy protecting from infection of immunostimulant-loaded nanoliposomes in zebrafish in vivo.

17 Jun 2014

Lipids efficiently kill leukemia cells

T cells use a novel mechanism to fight leukemia. They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules.

17 Jun 2014

Exercise transiently suppresses inflammation in rheumatic disease

Research findings presented today at the European League Against Rheumatism Annual Congress suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.

12 Jun 2014

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

New biometric wearable devices use scattered light to monitor glucose levels and pulse

Monitoring a patient's vital signs and other physiological parameters is a standard part of medical care, but, increasingly, health and fitness-minded individuals are looking for ways to easily keep their own tabs on these measurements. Enter the biometric watch.

11 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

ConforMIS announces positive study results of iTotal implant at BASK meeting

ConforMIS, Inc., a medical device company pioneering patient-specific orthopaedic implants, today announced results from several clinical research studies highlighting the benefits of the iTotal® patient-specific total knee replacement.

4 Jun 2014

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

EKF and GILUPI, announce results from collaborative work using GILUPI CellCollector and EKF Molecular’s PointMan DNA Enrichment technology.

From EKF Diagnostics 30 May 2014

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

In a new study, published in this week's issue of the journal Science, researchers show for the first time how the brain re-wires and fine-tunes its connections differently depending on the relative timing of sensory stimuli.

29 May 2014

New fNIRS -FD instrument can identify affected areas of brain

Monitoring the rehabilitation of patients with neurological damage caused by a stroke, has encouraged Mexican scientists to work in the design and manufacture of a functional infrared spectroscopy (fNIRS -FD ) instrument capable of identifying the affected areas of the brain and the sites that were activated while analyzing the oxygen content in blood flow during therapy.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

UCSB study shows that key protein in epithelial cells plays important roles in how cells sense direction

What do sled dogs and cell clusters have in common? According to research by UC Santa Barbara's Denise Montell, they both travel in groups and need a leader to make sure they all follow in the same direction.

23 May 2014

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.

21 May 2014

Researchers develop potential route to new therapies for treatment of Parkinson's disease

A biologist and a psychologist at the University of York have joined forces with a drug discovery group at Lundbeck in Denmark to develop a potential route to new therapies for the treatment of Parkinson's Disease (PD).

16 May 2014

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.

15 May 2014

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

14 May 2014

SGK1 enzyme, asthma and cancer therapies: an interview with Dr. Jonathan D. Powell, Johns Hopkins Kimmel Cancer Center

SGK1 stands for serum/glucocorticoid-regulated kinase 1. SGK1 is a member of the AGC kinase family, which is a huge family of kinases.

13 May 2014